Navigation Links
Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
Date:10/10/2007

PALO ALTO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today the appointment of its C.E.O., Belinda Tsao-Nivaggioli, Ph.D., to the additional role of Chairman of the Company's Board of the Directors. Dr. Tsao- Nivaggioli succeeds Nasser Menhall, who recently resigned from the Board to focus his time on other business ventures.

"I want to take this opportunity to thank Nasser for his many contributions and his invaluable leadership over many years and I wish him best of luck in his new ventures," stated Dr. Tsao-Nivaggioli. "I appreciate the Board of Directors' vote of confidence and I continue to be proud to be associated with this organization and its people. I look forward to leading this Company and to further leveraging our cellular energy technology to develop and commercialize pharmaceutical and dermaceutical products."

Prior to her current roles of CEO and Chairman, Dr. Tsao-Nivaggioli was Avicena's chief operating officer from 2002 to 2004. During her tenure with the Company, Dr. Tsao-Nivaggioli has expanded its intellectual property portfolio and built a substantial pipeline of pharmaceutical products, including drug candidates for the treatment of neurological disorders such as ALS, Huntington's and Parkinson's Disease. Dr. Tsao-Nivaggioli is also credited with solidifying the Company's relationship with the National Institutes of Health (NIH) as well as developing the Company's dermaceutical programs.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

Contact:

The Ruth Group (on behalf of Avicena Group)

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)

(646) 536-7033 / 7025

jmccargo@theruthgroup.com or jrando@theruthgroup.com


'/>"/>
SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Avicena to Advance Huntingtons Disease Clinical Program into Phase III
2. Study casts doubt on keyboard ills
3. Who Board To Discuss Asian Tsunami Related Health Issues
4. Abdominal Crunches Not The Best Option For Wash Board Abs.
5. Computer Keyboards In Hospitals Could Spread Infection To Patients
6. Flu, Boarded A Ship?
7. Skateboarding to health
8. Shangai Citizens to Monitor Billboards
9. Budhia Is Fine, Government-constituted Medical Board Reports False
10. Pharmacy Board Says Pharmacists Have Right To Refuse Morning-After Pill
11. 115 people on board a cruise liner taken ill due to suspected Norovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Today, the Whole-Food ... announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, ... Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 Aethlon ... Jim Joyce , Chairman and CEO, will be presenting at ... New York, NY at 2:15 p.m. ... participate in an Immunotherapy Panel discussion taking place at 3:15 ... available for replay approximately one hour after the conclusion of ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
Breaking Medicine Technology: